NCT06747936CompletedPhase 3
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients With Primary Hypercholesterolemia.
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 129 (actual)
- First submitted
- 19 Dec 2024
- Start date
- 3 Feb 2025
- Primary completion date
- 30 May 2025
- Lead sponsor
- Addpharma Inc.
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT06747936
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 129
- From 3 Feb 2025 to the primary completion date, 30 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with Secondary Hypercholesterolemia
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Patients with Primary Hypercholesterolemia
- Other inclusions applied
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Severance hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.